Inhibikase Therapeutics, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$4M
R&D
$30M
SG&A
$24M
D&A
$60K
Operating Income
$-52M
EBITDA
$-52M
Interest Expense
—
Other Income/Expense
$52M
Pretax Income
$-48K
Tax Provision
$0
Net Income
$-48M
Operating Margin
-1399.0%
Net Margin
-1299.0%
Effective Tax Rate
0.0%
Deferred Tax Assets
$0
DTA Valuation Allowance
$32M
Tax Credit Carryforwards
$0
NOL Carryforwards
$15M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
3.0%
Operating Lease Cost
$118K
Revenue YoY Variation
247.5%
Income YoY Variation
-81.8%